Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CLEC3B

CLEC3B

Brief Information

Name:Tenascin
Target Synonym:Glioma-associated-extracellular matrix antigen,GMEM,Neuronectin,Hexabrachion,Tenascin-C,TN-C,GP 150-225,TNC,Tenascin C,Deafness, Autosomal Dominant 56,Hexabrachion (Tenascin),Myotendinous Antigen,Cytotactin,HXB,JI,TN,Hexabrachion (Tenascin C, Cytotactin),Tenascin-C Additional Domain 1,Tenascin-C Isoform 14/AD1/16,150-225,DFNA56,GP,Tenascin,MGC167029
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Synonym Name

CLEC3B,Tetranectin,TN,TNA

Background

C-type lectin domain family 3 member B (CLEC3B) is also known as Tetranectin, Plasminogen kringle 4-binding protein, is a secreted homotrimer. CLEC3B contains 1 C-type lectin domain and mainly found in plasma. Tetranectin / CLEC3B binds to plasminogen and to isolated kringle 4. CLEC3B may be involved in the packaging of molecules destined for exocytosis. Decreased plasma Tetranectin or increased Tetranectin in stroma of cancers correlates with cancer progression and adverse prognosis.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
F16 IL2 fusion protein (Philogen) F-16-IL-2 Phase 2 Clinical Philogen Solid tumours; Carcinoma, Merkel Cell; Hemangiosarcoma; Breast Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung; Melanoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message